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ABSTRACT 
Background: The National Committee for Quality Assurance (NCQA) has developed 
Healthcare Effectiveness Data and Information Set (HEDIS®) measures for commercial and 
Medicaid health plans to promote health care quality improvement.  Two of these measures 
focus on follow-up care for children prescribed attention-deficit / hyperactivity disorder (ADHD) 
medications.  Success in the first measure (Initiation or INIT Phase) requires patients to have a 
qualifying claim for follow-up care within 30 days after the date of the first (index) prescription 
claim for an ADHD medication.  Success in the second measure (Continuation & Maintenance 
or C&M Phase) requires patients to have two additional qualifying claims for follow-up care 
within the 270 day period after the Initiation Phase (National Committee for Quality Assurance, 
2007). 
Objectives: To examine characteristics and utilization patterns for patient cohorts defined by 
performance on the two HEDIS® measures for follow-up care for children prescribed ADHD 
medication in order to identify potential opportunities for improving measure performance by 
health plans. 
Methods: From a commercial claims database of 17 million enrollees a study population was 
defined using the INIT measure eligibility criteria (6−12 years of age, ≥1 prescription for ADHD 
medication between 3-1-2007 and 2-29-2008, continuous enrollment for 120 days prior to first 
ADHD prescription [index] and 300 days following index, and no ADHD prescriptions for 120 
days prior to index). Success and failure cohorts for INIT and C&M measures, respectively, were 
compared on demographics and utilization patterns using two-sample t-tests for continuous 
variables and chi-squared tests for categorical variables. No adjustment was made for 
multiplicity. 
Results: Among INIT Phase failures, >15% of patients missed the 30-day mark for having a 
qualifying claim post index by ≤10 days.  INIT Phase failure was also a factor in C&M Phase 
failure with over 76% of C&M Phase failures occurring solely due to missing the qualifying 
follow-up visit within 30 days post index.  Pediatricians treated approximately 50% of patients 
eligible for the measure and had a lower success rate relative to some other specialties.  Patients 
with index prescriptions lower than the modal dose for each product, or with a dose titration 
within 60 days post index, had relatively higher success rates on the INIT Phase measure. 
Conclusions: Education for physicians and their staff focused on increasing awareness of the 
two ADHD HEDIS® measures and emphasizing the importance of follow-up within 30 days of 
initiation may help health plans improve their performance on these measures.   Pediatricians 
may be an efficient target audience for such education efforts due to the large number of ADHD 
HEDIS® eligible patients they treat and their relatively lower success rate on the measures.  
Education efforts should also reinforce clinical practice guidelines that discuss the importance of 
closely monitoring patients taking ADHD medications in order to titrate doses based upon 
tolerability and clinical response.  Additional research is needed to evaluate how interventions 
that incorporate these findings impact health plan performance on these ADHD HEDIS® 
measure and ultimately the quality of care for patients.  
 
 
 
 
 
 
 
 
BACKGROUND 
 
Attention-deficit / Hyperactivity Disorder 
Attention-deficit / hyperactivity disorder (ADHD) is one of the most common neurobehavioral 
disorders among children and adolescents.  Symptoms include difficulty focusing or paying 
attention, difficulty controlling impulsive behaviors, and, in some cases, hyperactivity (The 
ADHD Molecular Genetics Network, 2002).  These symptoms can lead to behavioral problems, 
academic underachievement, and difficulty developing and maintaining relationships (Pastor & 
Reuben, 2008).  While ADHD is usually diagnosed in childhood, it is not uncommon for it to 
persist into adulthood (The ADHD Molecular Genetics Network, 2002).  The Diagnostic and 
Statistical Manual of Mental Disorder from the American Psychiatric Association states that 3%-
7% of school aged children have ADHD (American Psychiatric Association, 2000).  However, 
these estimates are lower than prevalence rates reported in other studies.  Green, Wong, Atkins, 
Taylor, & Feinleib, 1999 reported prevalence rates among youth in the United States ranging 
from 3% to 16% depending upon the sampling design and restrictiveness of the definition used 
for ADHD.  In more recent years, the rate of ADHD diagnosis in the U.S. has increased from an 
average rate of 3% per year from 1997 to 2006 to 5.5% per year from 2003 to 2007 (Centers for 
Disease Control and Prevention, 2010).  The estimated prevalence of parents that reported 
having a child 4-17 years of age that had ever been diagnosed with ADHD was 9.5% or 5.4 
million children in 2007 (Centers for Disease Control and Prevention, 2010).  
 
In addition to being quite prevalent, ADHD is associated with significant economic burden.  
Pelham, Foster, & Robb, 2007 examined the economic burden of ADHD and estimated the total 
annual cost of illness at $14,576 per-child in 2005 dollars.  Assuming an ADHD prevalence of 
5%, and using the 2000 census of 60 million school-aged children in the United States, they 
extrapolated the per-patient estimates into an annual aggregate cost of illness of $42.5 billion.  
Included in this estimate were costs related to health and mental health services, education, as 
well as crime and delinquency.  While their annual aggregate cost was quite significant, they 
described them as conservative and more likely twice this amount since they cut across a number 
of domains and impact young people with the majority of their lives ahead of them.  It is clear 
from this information that the relatively high prevalence, and high economic burden make 
ADHD is a significant public health concern. (Pelham, Foster, & Robb, 2007). 
 
Many treatment options exist for children with ADHD including pharmacologic as well as non-
pharmacologic options such as behavioral therapy (American Academy of Pediatrics, Committee 
on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder, 2001).  
Pharmacologic treatment of ADHD is quite prevalent as evident from a 2007 estimate that 2.7 
million youth ages 4-17 years were taking medications for ADHD representing 66.3% of those 
with a current ADHD diagnosis (Centers for Disease Control and Prevention, 2010).  According 
to treatment guidelines from the American Academy of Pediatrics, stimulant medications are 
highly effective in managing symptoms of ADHD, and behavioral interventions are valuable as 
either primary or adjunctive treatment.  They also state that, while stimulant medications are 
generally safe, there are both minor and serious side effects that can often be managed through 
dose adjustments.  Thus, the guidelines recommend that clinicians start with a low dose and 
titrate upward to achieve optimal response while minimizing side effects when initiating 
treatment with stimulant medications.  Using this strategy, the guidelines point out, may result in 
the need to decrease the medication dose if higher doses result in side effects or no additional 
improvement in symptoms (American Academy of Pediatrics, Committee on Quality 
Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder, 2001).  The 
American Academy of Child and Adolescent Psychiatry state similar recommendations, and 
states that a consistent:  titration schedule, method for assessing drug response and managing 
treatment-related side effects, and schedule for monitoring long-term medication maintenance 
should be established by prescribers of stimulant medications for ADHD (American Academy of 
Child and Adolescent Psychiatry, 2002).  While the guidelines are clear, such recommendations 
don’t always translate into clinical practice.  One study surveyed families of children 4 to 15 
years of age diagnosed with ADHD to assess the number of follow-up visits with their primary 
care clinician or mental health specialists during a 6 month period.  An initial questionnaire was 
completed by parents and clinicians with a second questionnaire completed during an office visit 
6 months later.  There were 659 surveys returned (68% return rate), and the results showed that 
children had a median of one visit during the 6 month period.  The results were the same 
regardless of whether the children were receiving psychotropic medications, and the authors 
concluded that more follow-up visits are needed to permit appropriate monitoring and adjustment 
of medications (Gardner, Kelleher, Pajer, & Campo, 2004).  Another study utilized a 1-page 
chart abstraction tool to evaluate compliance with American Academy of Pediatrics practice 
guidelines for assessment and treatment of ADHD in children.  Pilot testing of the tool with 57 
children found that only 12% showed full compliance with the assessment guidelines and 44% 
with the treatment guidelines (Vreeman, Madsen, Vreeman, Carroll, & Downs, 2006).  
 
 
National Committee for Quality Assurance and the Healthcare Effectiveness Data and 
Information Set 
The National Committee for Quality Assurance (NCQA) is a private not-for-profit organization 
with a mission “to improve the quality of health care” (The National Committee for Quality 
Assurance, 2011).  As described within their vision, NCQA aspires “to transform health care 
quality through measurement, transparency and accountability” (The National Committee for 
Quality Assurance, 2011).  To accomplish this, they work with numerous diverse stakeholders to 
determine which quality issues are important, how they should be measured, and how to promote 
improvement within each measure. 
 
As part of these efforts, NCQA developed Healthcare Effectiveness Data and Information Set 
(HEDIS®) measures for commercial and Medicaid health plans to promote health care quality 
improvement.  Over 90% of health plans in the U.S. use HEDIS® to measure their performance 
and improve the quality of care provided to their members.  At present, there are 71 measures 
across 8 domains of care that are part of HEDIS®.  These measures allow health plans to 
benchmark or compare their performance against other plans and identify areas where they need 
to focus quality improvement efforts (National Committee for Quality Assurance).  NCQA has 
also developed a formal framework that allows health plans across the United States to become 
NCQA Accredited by implementing and reporting on a long list of quality-related standards they 
have established (The National Committee for Quality Assurance, 2011). 
 
In light of the high prevalence of ADHD among school-aged children, rapid growth in the use of 
ADHD medications with potentially serious side effects, and the high economic burden of 
disease, two HEDIS® measures were developed by NCQA focusing on follow-up care for 
children (ages 6-12) prescribed ADHD medications (National Committee for Quality Assurance, 
2009).  The measures focus on follow-up visits after ADHD medication treatment is initiated due 
to the importance of monitoring patient response so that dose adjustments can be made to 
maximize symptom control and minimize side effects (National Committee for Quality 
Assurance, 2009).  The measures are entitled “Follow-Up Care For Children Prescribed ADHD 
Medication: Initiation Phase” and “Follow-Up Care For Children Prescribed ADHD Medication: 
Continuation and Maintenance Phase” (National Committee for Quality Assurance, 2007).  
Below is a brief description for how health plans would determine their performance on each of 
the measures: 
• Initiation Phase Measure (INIT) - The percentage of members 6–12 years of age 
initiating ADHD medication, who had at least 1 qualifying claim for a follow-up visit 
during the 30-day period (initiation phase) after the first prescription observed during the 
reporting period (defined as the index prescription).  The fill date of that prescription is 
referred to as the index date (National Committee for Quality Assurance, 2007). 
• Continuation and Maintenance Phase Measure (C&M) - The percentage of members 6–
12 years of age initiating ADHD medication and continuing on therapy for at least 210 
days of the 300 days following the initiation phase, who had qualifying claims for at least 
1 follow-up visit in the initiation phase and at least 2 more qualifying claims for follow-
up visits in the 270 days following the 30-day initiation phase (National Committee for 
Quality Assurance, 2007). 
Commercial and managed Medicaid health plan performance on these measures, reported as the 
percent of patients meeting requirements for each phase, has been low ranging from 31 to 36% 
from 2005 to 2008 for the INIT phase, and 38 to 40% from 2007 to 2008 for the C&M phase 
(National Committee for Quality Assurance, 2009).  Programs and research focused on 
improving performance on these measures would contribute to public health by increasing 
follow-up care for children with ADHD.  This not only has the potential to benefit children with 
ADHD, but also their families and health plans participating in these measures.  The remainder 
of this paper is focused on one such research study that attempted to identify opportunities for 
improving health plan performance on the two ADHD HEDIS® measures for follow-up care. 
 
OBJECTIVES 
 
The objectives of this study were to compare patient characteristics and utilization patterns of 
cohorts defined based upon performance on specific requirements within the HEDIS® technical 
specifications for follow-up care for children prescribed ADHD medications (National 
Committee for Quality Assurance, 2007) with a focus on identifying specific issues that may 
impact performance on these quality measures.  Given the historically low performance on the 
two ADHD-related HEDIS® measures, identifying issues impacting performance may assist 
health plans in designing programs to improve follow-up care for children taking ADHD 
medications, and ultimately help them improve their performance on the two ADHD HEDIS® 
measures. 
 
 
 
 
STUDY DESIGN 
 
A retrospective analysis of medical and prescription claims data from a geographically diverse 
set of U.S. commercial health plan enrollees was conducted.  The 2008 HEDIS® technical 
specifications for ADHD follow-up care measures were used to approximate the HEDIS® 
eligible population and to define cohorts based on success or failure of each measure and 
selected measure criteria (National Committee for Quality Assurance, 2007).  Demographics, 
clinical characteristics, and utilization patterns were compared between relevant cohorts, and 
success rates for the INIT and C&M measures were calculated for selected strata of interest. 
 
METHODS 
 
Data Source 
The claims data examined in this study came from OptumInsight (formerly i3 Innovus).  This 
administrative claims database is Health Insurance Portability and Accountability Act (HIPAA) 
compliant and contains de-identified medical claims, pharmacy claims and enrollment 
information for 17 million commercial enrollees associated with a large, geographically diverse 
U.S. managed care health plan.  Only summary results were provided for review by the study 
sponsor, and the University of North Carolina Public Health Nursing Institutional Review Board 
(IRB) determined that this research did not require IRB approval.  
 
 
 
Study Population 
The inclusion criteria for the study were as follows:  1) patients having at least 1 prescription 
claim for an ADHD medication (see Table 1 for list of ADHD medications) between March 1, 
2007 and February 29, 2008; 2) patients at least 6 years of age on December 31, 2006 and less 
than 13 years of age on December 31, 2008; 3) patients having continuous enrollment with 
medical and pharmacy benefits for 120 days prior to the date of their first ADHD prescription 
during the study period (index date) and 300 days following the index date.  The exclusion 
criteria for the study were as follows:  1) patients having any medical claim for an inpatient stay 
for mental health or substance abuse 300 days following the index date; 2) patients having any 
prescription claim for an ADHD medication in the 120 days prior to the index date. 
 
There were two slight operational differences from those outlined in the ADHD HEDIS® 
technical specifications (National Committee for Quality Assurance, 2007):  1) the study used 
only birth year for age assignment since exact birth dates were not available within the data set; 
2) the study required longer continuous enrollment to allow follow-up on events after HEDIS® 
cutoff dates. 
 
 
 
Table 1. ADHD Medications Included in HEDIS Technical Specification
Amphetamine-dextroamphetamine (eg, Adderall®, Adderall XR®)
Methamphetamine
Methylphenidate (eg, Concerta®, Metadate®, Ritalin®, Ritalin RA®, Ritalin SR
Lisdexamfetamine dimesylate (eg, Vyvanse®)
Dexmethylphenidate (eg, Focalin®, Focalin XR®)
Dextroamphetamine (eg, Dexedrine®)
Atomoxetine (eg, Strattera®)  
 Cohort Definitions 
The study population was crafted to approximate the population eligible for the ADHD HEDIS® 
INIT measure and was defined as INIT Eligible. The INIT Eligible cohort was split into two 
mutually exclusive cohorts (INIT Success and INIT Failure) based on individual patients’ 
performances on the INIT measure which required a qualifying follow-up visit within 30 days 
following the index date.  Qualifying visits were identified based upon medical claims that had a 
procedure or revenue code defined within the HEDIS® technical specifications as qualified 
follow-up care. Visits without one of these specified codes would not qualify as follow-up care.  
The C&M Eligible cohort was defined as the subset of the INIT Eligible cohort that met an 
additional criterion of having at least 210 days of ADHD medication dispensed in the 300 days 
following the index date.  The C&M Eligible cohort was divided into a C&M Success cohort and 
a C&M Failure cohort.  The C&M Success cohort was defined as patients who met both of the 
following requirements:  1) having a qualifying follow-up visit within 30 days after the index 
date (INIT Success); 2) having at least two qualifying follow-up visits between day 31 and day 
300 post index.  Within the C&M Failure cohort, three subgroups were broken out for 
examination based on meeting these two previous requirements alone or in combination.  These 
three C&M failure subgroups were as follows:  1) patients who met the INIT Success 
requirement but had less than two qualifying C&M visits; 2) patients who failed the INIT phase 
follow-up, but had at least two qualifying C&M visits; 3) patients that failed both the INIT phase 
and C&M phase follow-up requirements.  A summary of these cohort descriptions along with the 
number of patients in each cohort are provided in Table 3 in the results. 
 
Statistical Methods 
The INIT Success and C&M Success cohorts were compared to their respective INIT Failure and 
C&M Failure cohorts on demographics, clinical characteristics, and utilization patterns derived 
from medical and prescription claims. Two-sample Student t tests were used to compare 
continuous variables. For categorical variables, chi-squared tests were used to compare patients 
with a given characteristic to those without that characteristic. No adjustments were made for 
multiplicity. 
 
RESULTS 
 
About half (9,028 of 17,746 [50.9%]) of the patients who met all eligibility criteria regarding 
enrollment, ADHD medication, age and hospitalization did not meet the requirement of having 
no ADHD medication prescription fills for ≥120 days prior to index.  This suggests that HEDIS® 
defined new starts represent about half of the 6- to 12-year-old population receiving these 
medications (see Table 2 for Sample Selection and Attrition).  The population that was C&M 
Eligible was smaller than the INIT Eligible population, as only 45.4% (3,962 of 8,718) of the 
INIT Eligible cohort had ≥210 days of ADHD medication therapy in the 300 days following the 
index date (Table 2). 
 
Meet Criteria Fail Criteria
Subjects commercially enrolled in health plan 
between November 1, 2006 and February 29, 2008 17,074,802 NA*
At least 1 ADHD medication fill between 
November 1, 2006 and February 29, 2008 183,798 0
With known gender and geographic region 183,287 511
≥6 years old on December 1, 2006 and ≤12 years 
old on December 31, 2008 32,872 150,415
benefits for 120 days prior to index date and 300 
days following 17,867 15,005
No inpatient stay for mental health or substance 
abuse 300 days following index date 17,746 121
No ADHD medication fills for 120 days prior to 
index date 8,718 9,028
INIT Eligible 8,718 NA*
date 3,962 4,756
C&M Eligible 3,962 NA*
*Not Applicable
Number of Subjects
Criteria
Table 2. Sample Selection and Attrition
 
 
As presented in Table 3, INIT Successes represented 40.4% of the INIT Eligible population.  
This is somewhat higher than the success rate of 35.8% for commercial health plans published by 
NCQA (National Committee for Quality Assurance, 2009).  C&M Successes represented 42.8% 
of the C&M Eligible population (Table 3), which is also higher than the published rate for 
commercial health plans of 40.2% (National Committee for Quality Assurance, 2009).  This left 
57.2% of the 3,962 patients as C&M Failures, having not met the requirements for a qualifying 
follow-up visit in the INIT phase and/or at least two qualifying follow-up visits in the C&M 
phase.  Of the C&M Failure patients, 94.3% did not have the required qualifying follow-up visit 
within 30 days post index and 76.1% failed solely because of missing that requirement. 
 
 Table 3. Cohort Descriptions and Patient Counts
Cohort Description
Number 
of 
INIT 
Eligible, %
C&M 
Eligible, %
C&M 
Failure, %
(1) INIT Eligible 8,718 100
(1A)
INIT Success (≥1 qualifying visit 
≤30 days post index date) 3,523 40.4
(1B)
INIT Failure (no qualifying visit 
≤30 days post index date) 5,195 59.6
(2) C&M Eligible 3,962 100
(2A)
AND ≥2 qualifying visits in 
C&M) 1,697 42.8
(2B)
C&M Failure (INIT Failure OR 
<2 qualifying visits in C&M) 2,265 57.2
(2B)
OR <2 qualifying visits in 
C&M) 2,265 100
(2Bi)
AND <2 qualifying visits in 
C&M) 130 3.3 5.7
(2Bii)
C&M Failure (INIT Failure AND 
≥2 qualifying visits in C&M) 1,723 43.5 76.1
(2Biii)
C&M Failure (INIT Failure AND 
<2 qualifying visits in C&M) 412 10.4 18.2
 
Initiation (INIT) Phase Results 
As presented in Table 4, the eligible study population (N=8,718) had a mean age of 9.4 years 
and 71.4% were male.  The 59.6% of patients who failed to have at least 1 qualifying INIT visit 
were less likely than the INIT Successes to have an ADHD diagnosis (79.6% versus 89.4%), to 
be treated by a psychiatrist (5.3% versus 10.3%), and to have a dose titration in the first 60 days 
(16.1% versus 25.2%), P<0.001 for all.  Dose titration was defined as any increase in dose of the 
index medication during the period index date plus 1 day through index date plus 60 days.  
Relative to the INIT Success patients, a higher proportion of INIT Failure patients were in the 
South region (61.5% versus 58.2%; P<0.001) and a lower proportion were in the Northeast 
region (5.4% versus 7.8%; P<0.001).  Patients in the South and Northeast regions had INIT 
success rates of 39.1% and 49.3%, respectively.  INIT Failures were more likely to be treated by 
a pediatrician than INIT Successes (53.7% versus 44.9%; P<0.001).  Pediatricians accounted for 
50.2% of index prescribers, the highest of any specialty, yet the INIT success rate of 36.2% was 
below the overall rate.  The 7.3% of INIT Eligible patients for whom a psychiatrist prescribed 
their index medication had a success rate of 56.7%.  Of INIT Failures, 15.1% had a follow-up 
visit with a qualifying code between days 31 and 40 (or within 10 days after the HEDIS®-
specified 30-day post-index cutoff date for INIT Success).  More than one third (34.9%) of INIT 
Failure patients had a qualifying visit within 60 days post index (i.e. day 31 to day 60).  The 
INIT success rate for patients whose index prescription was dispensed with ≤29 days of therapy 
was 51.6%.  For patients with an index prescription of at least 60 days of therapy, the success 
rate was 30.2%.  INIT Success patients were more likely than INIT Failures to have an index 
prescription that is less than the modal dose (25.2% versus 21.6%; P<0.001) and the INIT 
success rate for patients starting at a dose lower than the mode was 44.1%.  When reviewing 
these results, it is important to focus on the magnitude of the differences reported since many of 
the P-values are statistically significant due to the large sample size for each of the cohorts.  
 
 
 
Table 4. HEDIS® Initiation Phase Results
Patient Characteristics
(1) INIT Eligible 
(N=8,718)
(1A) INIT Success 
(N=3,523)
(1B) INIT Failure 
(N=5,195)
(1A) vs (1B) 
P  Value
INIT Success 
Rate, %
Age (continuous) Mean (SD) 9.4 (1.4) 9.3 (1.4) 9.4 (1.4) <0.001 NA*
Sex
     Male n (%) 6,222 (71.4) 2,520 (71.5) 3,702 (71.3) 0.785 40.5
     Female n (%) 2,496 (28.6) 1,003 (28.5) 1,493 (28.7) 0.785 40.2
Geographic region
     Northeast n (%) 558 (6.4) 275 (7.8) 283 (5.4) <0.001 49.3
     Midwest n (%) 2,188 (25.1) 915 (26.0) 1,273 (24.5) 0.121 41.8
     South n (%) 5,246 (60.2) 2,051 (58.2) 3,195 (61.5) 0.002 39.1
     West n (%) 726 (8.3) 282 (8) 444 (8.5) 0.369 38.8
Diagnosis of ADHD (on any pre- or post-index 
medical claim) n (%) 7,284 (83.5) 3,150 (89.4) 4,134 (79.6) <0.001 43.2
Count of pre-index prescription claims (non-
ADHD)
Mean (SD) 2.5 (3.5) 3.1 (3.9) 2.15 (3.1) <0.001 NA*
Index prescriber specialty
     Family practice n (%) 969 (11.1) 334 (9.5) 635 (12.2) <0.001 34.5
     Internal medicine n (%) 107 (1.2) 37 (1.0) 70 (1.3) 0.216 34.6
     Neurology n (%) 383 (4.4) 139 (3.9) 244 (4.7) 0.093 36.3
     Pediatrics n (%) 4,374 (50.2) 1,582 (44.9) 2,792 (53.7) <0.001 36.2
     Psychiatry n (%) 640 (7.3) 363 (10.3) 277 (5.3) <0.001 56.7
     Unknown or other n (%) 2,245 (25.7) 1,068 (30.3) 1,177 (22.7) <0.001 47.6
Categories of day supply for index medication
     ≤29 days n (%) 697 (8.0) 360 (10.2) 337 (6.5) <0.001 51.6
     30–69 days n (%) 7,723 (88.6) 3,073 (87.2) 4,650 (89.5) <0.001 39.8
     ≥60 days n (%) 298 (3.4) 90 (2.6) 208 (4.0) <0.001 30.2
Categories of dose level for index medication
     Less than mode n (%) 2,012 (23.1) 888 (25.2) 1,124 (21.6) <0.001 44.1
     Modea n (%) 3,746 (42.9) 1,537 (43.6) 2,209 (42.5) 0.306 41.0
     Greater than mode n (%) 2,960 (33.9) 1,098 (31.2) 1,862 (35.8) <0.001 37.1
Dose titration ≤60 days post index date n (%) 1,726 (19.8) 889 (25.2) 837 (16.1) <0.001 51.5
Days from index to first qualifying visit
     1–21 days n (%) 2,456 (28.2) 2,456 (69.7) 0 (0.0) <0.001 100
     22–30 days n (%) 1,067 (12.2) 1,067 (30.3) 0 (0.0) <0.001 100
     31–40 days n (%) 783 (8.9) 0 (0.0) 783 (15.1) <0.001 0
     41–60 days n (%) 1,030 (11.8) 0 (0.0) 1,030 (19.8) <0.001 0
     61–90 days n (%) 867 (9.9) 0 (0.0) 867 (16.7) <0.001 0
     ≥90 days n (%) 2,019 (23.2) 0 (0.0) 2,019 (38.9) <0.001 0
     No qualifying visit ≤300 days post index n (%) 496 (5.7) 0 (0.0) 496 (9.5) <0.001 0
Nonqualifying visit within 30 days post index n (%) 1,058 (12.1) 493 (14.0) 565 (10.9) <0.001 46.6
*Not Applicable.  aModal doses for each drug category were as follows: amphetamine-dextroamphetamine, 10 mg; atomoxetine, 40 mg; dexmethylphenidate, 10 
mg; dextroamphetamine, 10 mg; methylphenidate, 20 mg; lisdexamfetamine dimesylate, 30 mg.
 
Continuation and Maintenance (C&M) Phase Results 
As presented in Table 5, the C&M Eligible study population (N=3,962) had a mean age of 9.2 
years and 73.4% were male.  C&M Success patients were more likely to have a diagnosis of 
ADHD (92.3% versus 82.9%; P<0.001), had a greater number of prescription claims in the pre-
index period (4.0 versus 3.2; P<0.001), and were more likely to be treated by a psychiatrist 
(11.6% versus 7.0%; P<0.001) than C&M Failure patients.  Relative to the C&M Success 
patients, a lower proportion of C&M Failure patients were in the Northeast region (6.2% versus 
8.3%; P=0.012).  The C&M success rate was highest in the Northeast region at 50.0% and 
lowest in the West region at 38.0%.  C&M Failures were more likely to be treated by a 
pediatrician than C&M Successes (53.4% versus 42.4%; P<0.001).  In the C&M Eligible 
population, pediatricians accounted for 48.7% of index prescribers, the highest of any specialty.  
The C&M success rate for pediatrician index prescribers of 37.3% was below the overall C&M 
success rate of 42.8%.  The 8.9% of C&M Eligible patients for whom a psychiatrist prescribed 
their index medication had a success rate of 55.2%, the highest of any index prescriber and well 
above the overall C&M success rate.  It is notable that 16.9% of C&M Failure patients had their 
first qualifying follow-up visit within 10 days after the HEDIS®-specified 30-day post index date 
(i.e., Day 31 to Day 40).  Additionally, 37.3% of C&M Failure patients had their first qualifying 
follow-up visit within 60 days post index (i.e. Day 31 to Day 60).  There were 51.3% of C&M 
Failures that had their first qualifying follow-up visit greater than 60 days post index, and 5.6% 
that had no qualifying visit within 300 days post index. 
 
 
  
Table 5. HEDIS® Continuation and Maintenance Phase Results
Patient Characteristics
(2)        
C&M 
Eligible 
(N=3,962)
(2A)       
C&M 
Success 
(N=1,697)
(2B)        
C&M 
Failure 
(N=2,265)
(2A) vs (2B) 
P  Value
C&M 
Success Rate, 
%
(2Bi)          
C&M Failure 
(INIT Success 
AND <2 
Qualifying 
Visits in 
C&M) 
(N=130)
(2Bii)          
C&M Failure 
(INIT Failure 
AND ≥2 
Qualifying 
Visits in C&M) 
(N=1,723)
(2Biii)         
C&M Failure 
(INIT Failure 
AND <2 
Qualifying 
Visits in C&M) 
(N=412)
Age (continuous) Mean (SD) 9.2 (1.4) 9.2 (1.4) 9.2 (1.4) 0.461 NA* 9.1 (1.3) 9.2 (1.4) 9.3 (1.4)
Sex
     Male n (%) 2,909 (73.4) 1,240 (73.1) 1,669 (73.7) 0.664 42.6 96 (73.9) 1,265 (73.4) 308 (74.8)
     Female n (%) 1,053 (26.6) 457 (26.9) 596 (26.3) 0.664 43.4
Geographic region
     Northeast n (%) 282 (7.1) 141 (8.3) 141 (6.2) 0.012 50.0 5 (3.9) 118 (6.9) 18 (4.4)
     Midwest n (%) 1,094 (27.6) 482 (28.4) 612 (27.0) 0.335 44.1 45 (34.6) 463 (26.9) 104 (25.2)
     South n (%) 2,249 (56.8) 946 (55.8) 1,303 (57.5) 0.263 42.1 68 (52.3) 1,002 (58.2) 233 (56.6)
     West n (%) 337 (8.5) 128 (7.5) 209 (9.2) 0.06 38.0 12 (9.2) 140 (8.1) 57 (13.8)
Diagnosis of ADHD (on 
any pre- or post-index 
medical claim) n (%) 3,445 (86.9) 1,567 (92.3) 1,878 (82.9) <0.001 45.5 108 (83.1) 1,525 (88.5) 245 (59.5)
Count of pre-index 
prescription claims (non-
ADHD) Mean (SD) 3.5 (4.1) 4.0 (4.4) 3.2 (3.8) <0.001 NA* 2.5 (2.9) 3.4 (3.9) 2.3 (3.2)
Most frequent post-index provider specialty
     Family practice n (%) 359 (9.1) 135 (8.0) 224 (9.9) 0.036 37.6 18 (13.9) 155 (9.0) 51 (12.4)
     Internal medicine n (%) 40 (1.0) 14 (0.8) 26 (1.2) 0.314 35.0 0 (0.0) 18 (1.0) 8 (1.9)
     Neurology n (%) 174 (4.4) 68 (4.0) 106 (4.7) 0.306 39.1 3 (2.3) 94 (5.5) 9 (2.2)
     Pediatrics n (%) 1,929 (48.7) 719 (42.4) 1,210 (53.4) <0.001 37.3 75 (57.7) 913 (53.0) 222 (53.9)
     Psychiatry n (%) 355 (8.9) 196 (11.6) 159 (7.0) <0.001 55.2 3 (2.3) 133 (7.7) 23 (5.6)
     Unknown or other n (%) 1,105 (27.9) 565 (33.3) 540 (23.8) <0.001 51.1 31 (23.9) 410 (23.8) 99 (24.0)
Days from index to first 
qualifying visit
     1–21 days n (%) 1,273 (32.1) 1,197 (70.5) 76 (3.4) <0.001 94.0 76 (58.5) 0 (0.0) 0 (0.0)
     22–30 days n (%) 554 (14.0) 500 (29.5) 54 (2.4) <0.001 90.3 54 (41.5) 0 (0.0) 0 (0.0)
     31–40 days n (%) 382 (9.6) 0 (0.0) 382 (16.9) <0.001 0.0 0 (0.0) 373 (21.7) 9 (2.2)
     41–60 days n (%) 462 (11.7) 0 (0.0) 462 (20.4) <0.001 0.0 0 (0.0) 442 (25.7) 20 (4.9)
     61–90 days n (%) 383 (9.7) 0 (0.0) 383 (16.9) <0.001 0.0 0 (0.0) 361 (21.0) 22 (5.3)
     ≥90 days n (%) 780 (19.7) 0 (0.0) 780 (34.4) <0.001 0.0 0 (0.0) 547 (31.8) 233 (56.6)
     No qualifying visit 
≤300 days post index n (%) 128 (3.2) 0 (0.0) 128 (5.6) <0.001 0.0 0 (0.0) 0 (0.0) 128 (31.1)
*Not Applicable
DISCUSSION 
 
Key findings from the study were that more than 15% of INIT Failures missed the 30-day mark 
for having a qualifying claim post index by ≤10 days, and that INIT phase failure was also a 
factor in C&M phase failure with over 76% of C&M Failures occurring solely due to missing the 
qualifying follow-up visit within 30 days post index.  This suggests that many physicians may 
not be monitoring patients appropriately after prescribing ADHD medications, and that 
continuing education may be needed to reinforce the importance of closely monitoring patients 
so that ADHD medication doses can be titrated based upon side effects and clinical response.  
This is in the interest of patient safety and for maximizing clinical response, and is consistent 
with guidelines from the American Academy of Pediatrics (American Academy of Pediatrics, 
Committee on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity 
Disorder, 2001) and the American Academy of Child and Adolescent Psychiatry (American 
Academy of Child and Adolescent Psychiatry, 2002).  Higher success rates observed for patients 
that had an initial day supply for their index medication of ≤29 days, a dose titration within 60 
days post index date, or an index dose level that was less than the modal dose for their particular 
ADHD medication also support the idea that increased monitoring of patients by healthcare 
providers would lead to increased performance on both ADHD HEDIS® measures.  It must also 
be acknowledged that low ADHD HEDIS® measure performance cannot be exclusively 
attributed to poor monitoring and adherence to practice guidelines by physicians.  Patients and 
caregivers also share a responsibility in following recommendations from health care providers, 
and ensuring that they show up for follow-up visits.  There may also be other factors that 
influence follow-up care that were not evident within these results, or were not assessed within 
the study.  One potential example of an issue that was not available in the data and could not be 
assessed is socioeconomic status.  If socioeconomic data were available for analysis, it is 
possible that we would find that lower socioeconomic or income status would be associated with 
lower ADHD HEDIS® measure success rates since patients and caregivers may not have access 
to the transportation necessary to make their scheduled follow-up visits.  Since health plans may 
find it difficult to address other factors such as the socioeconomic example above, they are likely 
to consider health care provider education for improving their ADHD HEDIS® measure 
performance since it is a more feasible option.   
 
Physicians represent one part of the overall care team that interacts with patients receiving 
ADHD medications and their caregivers.  For this reason, it seems prudent to ensure that 
education efforts target not only physicians, but also other clinicians and support staff so that all 
members of the care team can work towards a common goal of encouraging appropriate 
monitoring and follow-up.  As part of these efforts, health plans could consider encouraging 
clinicians and their staff to limit initial prescriptions for ADHD medications to no more than a 2-
week supply and subsequent prescriptions to no more than a 30-day supply.  This may help 
ensure that patients adhere to recommendations for follow-up care and thereby address the 
patient and caregiver roles in ADHD HEDIS® measure performance since they would be 
required to follow-up in order to obtain additional prescriptions.  While it seems likely that such 
an approach would improve monitoring and ADHD HEDIS® measure performance, additional 
research is needed to confirm these assertions and to determine whether health plans would 
consider implementing such policy-related changes.  One study examined the impact of self-
assessment and targeted training for physicians on practice performance with respect to 
adherence to evidenced-based recommendations for care.  Based upon improved adherence to 10 
specific recommendations from the American Academy of Pediatrics Guidelines for ADHD, the 
authors concluded that practice assessment and system-based training may be a cost-effective 
strategy for improving practice performance (Homer, Horvitz, Heinrich, Forbes, Lesneski, & 
Phillips, 2004).  These data provide evidence suggesting that targeted education and assessment 
may indeed be an effective method for improving adherence to guidelines, and thereby ADHD 
HEDIS® measure performance.   
 
In targeting education efforts focused on improving follow-up and ADHD HEDIS® performance, 
it may be an efficient approach to initially focus on pediatricians since they treated 
approximately 50% of patients eligible for the measures and collectively had lower performance 
on the measures relative to some other specialties.  In contrast, psychiatrists treated less than 
10% of the patients eligible and collectively achieved higher performance on the follow-up 
measures relative to other specialties.  This may be because patients seeing psychiatrists have a 
higher comorbid disease burden and therefore experience a corresponding increase in qualifying 
follow-up visits.  The >50% success rates for patients that had a psychiatrist as their index 
prescriber is still lower than one might expect, and leaves plenty of room for improvement.  
Though the database used for these analyses included a wide geographic representation across 
the United States, there is no guarantee that these results are generalizable to other populations.  
Thus, it may be helpful for health plans to examine their own ADHD HEDIS® measure 
performance by specialty and focus their efforts on specialties that have lower performance and 
treat a larger proportion of patients eligible for the measures.  
 
Additional analyses were conducted to examine whether coding issues on medical claims 
contributed to low performance on the two ADHD HEDIS® measures.  While results from these 
analyses did not warrant inclusion in the results section, discussion of how the codes were 
examined may be helpful for health plans wishing to exclude coding issues as a factor 
contributing to ADHD HEDIS® measure performance.  Claims for patients that failed the INIT 
Phase measure were examined for non-qualifying codes that appeared on medical claims within 
the 30 day post index period based on the ADHD HEDIS® technical specifications (National 
Committee for Quality Assurance, 2007).  The rationale for this was to identify codes that may 
be related to ADHD follow-up that aren’t included as qualifying codes within the ADHD 
HEDIS® technical specifications in order to determine how many of the patients that failed the 
INIT Phase measure could become INIT Successes if the technical specifications were 
broadened.  One of the top 15 non-qualifying codes appearing on medical claims within the 30 
day INIT Phase period was determined to be potentially related to ADHD follow-up among 
patients that were INIT Failures.  However, this code was only used on 50 claims impacting 29 
unique patients and couldn’t be attributed exclusively to ADHD-related follow-up.  Even if it 
could be verified that claims with this non-qualifying code were related to ADHD follow-up 
care, there would be a negligible impact on INIT Phase HEDIS® performance since there were so 
few patients identified with these codes present during the INIT Phase.  A similar analysis was 
done to examine non-qualifying codes on claims among C&M phase failures, and the findings 
were similar.  Thus, it was determined that issues related to medical coding did not significantly 
impact performance on ADHD HEDIS® follow-up measures and that education focused on 
improving coding practices would not be an efficient target for improving performance in the 
population examined.  Other health plans may still want to consider such issues when identifying 
opportunities for improving ADHD HEDIS® performance within their population.  
 
One limitation to this study is that there is no way to determine the impact of follow-up that 
occurred where an associated medical claim was not submitted by the healthcare provider.  
Another limitation of these study results is that they may not be generalizable to other health 
plans or populations.  Finally, the cohort definitions used had some slight operational differences 
from those outlined in the ADHD HEDIS® technical specifications (see methods section) so 
could be a limitation since they may not exactly reflect the population used to report results to 
NCQA. 
 
SUMMARY 
 
The following focus areas may help improve monitoring of patients started on ADHD 
medications, and may assist health plans improve their performance on the ADHD HEDIS® 
measures: 
 
1) Develop education programs for physicians and their staff focused on appropriate prescribing 
and monitoring of patients started on ADHD medications.  These programs should be based on 
published practice guidelines from the American Academy of Pediatrics, Committee on Quality 
Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder, 2001 and the 
American Academy of Child and Adolescent Psychiatry, 2002.  Education on the two ADHD 
HEDIS® measures, particularly the requirement for follow-up within 30 days after initiation, 
would also help to increase health care provider awareness of the measures and lead to increased 
focus on ensuring that patients receiving ADHD medications receive the required follow-up for 
HEDIS® measure success.  Consideration could also be given to suggesting that prescribers limit 
initial prescriptions to a 2-week supply and follow-up prescriptions to no more than a 30-day 
supply in order to help ensure patients follow-up as requested by their provider. 
 
2) Pediatricians may be an efficient target audience due to the number of eligible patients they 
treat and their relatively lower success rate on these measures (at least within the large 
population studied).  Health plans should evaluate their own ADHD HEDIS® measure 
performance by physician specialty in order to identify lower performing specialties that treat a 
large number of eligible patients and verify that pediatricians are an appropriate target audience.  
As ADHD HEDIS® measure performance improves among those specialties initially targeted, 
education efforts can then be expanded to other specialties in an ongoing effort to improve 
aggregate performance for the entire health plan. 
 
Future research is needed to evaluate the impact of interventions that incorporate these 
suggestions on ADHD HEDIS® measure performance for health plans.  It seems likely that 
improved performance on these measures would mean that more children are receiving closer 
monitoring of their ADHD therapy.  Whether such monitoring is “appropriate” based on the 
standards established within published guidelines needs to be examined, along with whether 
interventions focused on improving the quality of care for children receiving ADHD medications 
ultimately translates into improved public health by reducing the overall disease burden of 
ADHD. 
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